| Name | Title | Contact Details |
|---|
Alameda Hospital is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Alameda Hospital is based in Alameda, CA. You can find more information on Alameda Hospital at www.alamedahospital.org
Gateway EDI Inc is a Saint Louis, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
SCYNEXIS, Inc. is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. Our scientists have extensive experience in the life sciences industry having, together and individually, been involved in the discovery and development of innovative medicines over a broad range of therapy areas. We are developing our lead product candidate, SCY-078, a novel antifungal in Phase 2, as a novel oral and intravenous drug for the treatment of serious and life-threatening invasive fungal infections in humans.
UT Medical Group is the private practice arm of the University of Tennessee Health Science Center (UTHSC) faculty. Because the physicians in our group are actively involved in teaching and research, they remain current with the latest medical developments. As a not-for-profit, non-tax-supported group practice, UT Medical Group is dedicated to quality patient care, medical education, and medical research. This allows us to offer many unique, advanced health care services to people in the Mid-South at competitive prices. Ties to UTHSC allow the physicians at UT Medical Group access to the latest treatments, special protocols and labs, as well as a broad spectrum of professionals with advanced degrees in nursing, nutrition, pharmacology, psychology, and more. This involvement benefits not only our patients' treatments, but keeps the physicians at the top of their fields.
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte`s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte`s 6mm HAVs for AV access for performing hemodialysis was the first product candidate to receive the FDA`s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation, and the HAV technology received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.